Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Completion of preclinical data package for RAD 402

Tuesday, December 10, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has completed the preclinical data package for RAD 402, marking a crucial step in its development. This achievement aligns with the company's ongoing efforts to advance its clinical programs, including recent positive updates across four initiatives. The completion of this data package is expected to facilitate further clinical trials.
Price reaction · baseline $9.18 (2024-12-09 close) · hit pre-market · 1 other RADX headline(s) in the window, move may be shared
day 0 close
-28.3%
day 1
-37.6%
day 3 · peak
-38.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Completion of preclinical data package for RAD 402 is a significant milestone.
  • Positive clinical updates across multiple programs indicate progress.
  • IND approval from the FDA for Phase I study shows regulatory support.

Full Press Release Details

• Announcements
• Price Sensitive
• December 10, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 3, 2024
• Announcements
• March 1, 2024
• Announcements
• January 24, 2024
• Announcements
• November 19, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD 402?

RAD 402 is a therapeutic candidate developed by Radiopharm Theranostics.

What milestone has Radiopharm achieved?

Radiopharm has completed the preclinical data package for RAD 402.

What does the completion of preclinical data mean?

It signifies readiness to advance to clinical trials for RAD 402.

Has RAD 402 received FDA approval?

The article does not specify FDA approval for RAD 402, but mentions IND approval for another program.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics RAD 402 preclinical data clinical trials FDA approval
Last updated: Dec 10, 2024